Insider Selling: BioLife Solutions, Inc. (NASDAQ:BLFS) CMO Sells $201,719.32 in Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) CMO Todd Berard sold 8,902 shares of BioLife Solutions stock in a transaction on Tuesday, April 1st. The stock was sold at an average price of $22.66, for a total transaction of $201,719.32. Following the sale, the chief marketing officer now directly owns 135,956 shares in the company, valued at $3,080,762.96. This trade represents a 6.15 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Todd Berard also recently made the following trade(s):

• On Tuesday, March 11th, Todd Berard sold 1,577 shares of BioLife Solutions stock. The stock was sold at an average price of $25.00, for a total value of $39,425.00.
• On Monday, March 3rd, Todd Berard sold 424 shares of BioLife Solutions stock. The shares were sold at an average price of $25.46, for a total value of $10,795.04.
• On Wednesday, February 12th, Todd Berard sold 102 shares of BioLife Solutions stock. The stock was sold at an average price of $26.54, for a total value of $2,707.08.
• On Monday, January 6th, Todd Berard sold 343 shares of BioLife Solutions stock. The shares were sold at an average price of $27.02, for a total value of $9,267.86.

BioLife Solutions Price Performance

BLFS opened at $20.88 on Friday. The company has a quick ratio of 1.78, a current ratio of 2.78 and a debt-to-equity ratio of 0.03. The company’s 50-day moving average price is $25.87 and its 200 day moving average price is $25.50. BioLife Solutions, Inc. has a fifty-two week low of $14.84 and a fifty-two week high of $29.55. The firm has a market cap of $981.36 million, a price-to-earnings ratio of -19.70 and a beta of 2.04.

BioLife Solutions (NASDAQ:BLFS) last announced its quarterly earnings results on Monday, March 3rd. The medical equipment provider reported $0.26 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.32. BioLife Solutions had a negative return on equity of 6.61% and a negative net margin of 38.98%. The business had revenue of $22.71 million for the quarter, compared to analysts’ expectations of $21.73 million. During the same period in the prior year, the firm earned ($0.21) EPS. As a group, sell-side analysts expect that BioLife Solutions, Inc. will post -0.3 earnings per share for the current year.

Hedge Funds Weigh In On BioLife Solutions

Several hedge funds and other institutional investors have recently modified their holdings of the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in BioLife Solutions by 13.2% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 70,686 shares of the medical equipment provider’s stock valued at $1,835,000 after purchasing an additional 8,258 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of BioLife Solutions during the fourth quarter valued at approximately $31,000. Point72 Asset Management L.P. acquired a new position in shares of BioLife Solutions during the fourth quarter worth approximately $11,113,000. ProShare Advisors LLC bought a new position in BioLife Solutions in the 4th quarter worth approximately $282,000. Finally, Millennium Management LLC grew its holdings in BioLife Solutions by 49.1% in the 4th quarter. Millennium Management LLC now owns 1,145,347 shares of the medical equipment provider’s stock worth $29,733,000 after buying an additional 377,111 shares in the last quarter. Institutional investors and hedge funds own 93.24% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently issued reports on the stock. Northland Securities upped their price target on shares of BioLife Solutions from $28.00 to $31.00 and gave the company an “outperform” rating in a report on Wednesday, January 8th. Benchmark reaffirmed a “buy” rating and set a $30.00 price target on shares of BioLife Solutions in a research report on Thursday, December 19th. KeyCorp boosted their price objective on BioLife Solutions from $30.00 to $33.00 and gave the company an “overweight” rating in a report on Friday, December 13th. HC Wainwright increased their target price on BioLife Solutions from $27.00 to $30.00 and gave the stock a “buy” rating in a report on Thursday, March 6th. Finally, StockNews.com downgraded BioLife Solutions from a “hold” rating to a “sell” rating in a report on Monday, March 31st. One equities research analyst has rated the stock with a sell rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, BioLife Solutions has a consensus rating of “Moderate Buy” and an average price target of $31.17.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.